Pure Global AI
NCT06126718Not yet recruiting

Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects

BioRay Pharmaceutical Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
BR201
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
BioRay Pharmaceutical Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Nov 01, 2023
End date
Aug 01, 2024
Enrollment
88 participants
Primary outcome

AUC0-inf,Cmax

Summary

This is a randomized, open-label, controlled Phase I study of BR201 administered by
 subcutaneous injection. This study will characterize the pharmacokinetic, safety and
 immunogenicity of BR201 versus Cosentyx（Secukinumab ） in healthy male subjects after a single
 dose.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06126718
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06126718 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioRay Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Psoriasis. Target enrollment is 88 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.